Addressing these gaps systematically through well-designed preclinical studies, biomarker development programs, and carefully conducted clinical trials will be essential for determining whether this approach can fulfill its theoretical promise of improving outcomes for patients with CD30-positive mycosis fungoides. Here, TNFRSF8 is linked to mycosis fungoides.